
Please try another search
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Michael F. Cola | 64 | 2019 | Independent chairman of the Board |
Mark Stenhouse | 58 | 2020 | Independent Director |
Frank L. Karbe | 57 | 2022 | Independent Director |
Theodore R. Schroeder | 70 | 2025 | Director |
James Newman Topper | 63 | 2022 | Independent Director |
Heidi Kunz Fields | 70 | 2019 | Independent Director |
Asit Parikh | 53 | 2019 | Independent Director |
Steven L. Basta | 59 | 2025 | CEO, President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review